TREATMENT OF PSORIATIC ARTHRITIS WITH HOKT3Y1 (ALA-ALA)

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Psoriatic arthritis is a chronic inflammatory or swelling type of arthritis that occurs in approximately 7% of people with the skin disorder psoriasis. The cause of psoriatic arthritis is not known. Studies have shown that a particular type of white blood cell know as T-cells may be involved in the development of psoriasis and psoriatic arthritis. hOKT3 1 (Ala-Ala) is a new drug (a monoclonal antibody) that binds to T-cells and affects there function. This trial will examine the safety and effectiveness of hOKT3 1 (Ala-Ala) in patients with psoriatic arthritis, as well as the way the medication affects the immune system.